Mitsubishi UFJ Trust & Banking Corp Buys 11,214 Shares of Boston Scientific Co. (NYSE:BSX)

Mitsubishi UFJ Trust & Banking Corp increased its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 1.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 843,293 shares of the medical equipment provider's stock after acquiring an additional 11,214 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.06% of Boston Scientific worth $75,323,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 132,890,784 shares of the medical equipment provider's stock worth $11,869,805,000 after acquiring an additional 1,600,062 shares during the period. State Street Corp boosted its stake in Boston Scientific by 2.3% in the 3rd quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after purchasing an additional 1,389,172 shares during the period. Wellington Management Group LLP grew its holdings in Boston Scientific by 2.2% during the 3rd quarter. Wellington Management Group LLP now owns 32,820,828 shares of the medical equipment provider's stock valued at $2,750,385,000 after buying an additional 718,515 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Boston Scientific by 1.7% during the third quarter. Geode Capital Management LLC now owns 29,584,841 shares of the medical equipment provider's stock valued at $2,469,607,000 after buying an additional 480,729 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Boston Scientific by 5.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,475,031 shares of the medical equipment provider's stock worth $756,990,000 after buying an additional 456,654 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at approximately $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at approximately $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 137,302 shares of company stock valued at $14,319,269 over the last ninety days. 0.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BSX shares. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. JPMorgan Chase & Co. upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a report on Monday, December 16th. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research note on Friday, January 10th. Royal Bank of Canada upped their target price on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, Piper Sandler lifted their price target on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $108.91.

Boston Scientific Trading Down 1.5 %

Boston Scientific stock traded down $1.51 during trading hours on Friday, reaching $99.29. The company had a trading volume of 7,402,670 shares, compared to its average volume of 6,051,507. The firm has a market cap of $146.86 billion, a price-to-earnings ratio of 79.43, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 12-month low of $66.80 and a 12-month high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The company has a 50-day moving average price of $102.16 and a 200 day moving average price of $93.11.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.